- PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
- PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
- PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
- Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
- PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
- PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
More ▼
Key statistics
On Tuesday, Procept Biorobotics Corp (PRCT:NMQ) closed at 63.16, -17.97% below its 52-week high of 77.00, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 61.91 |
---|---|
High | 63.46 |
Low | 61.84 |
Bid | 58.68 |
Offer | 65.24 |
Previous close | 63.16 |
Average volume | 645.64k |
---|---|
Shares outstanding | 51.42m |
Free float | 48.71m |
P/E (TTM) | -- |
Market cap | 3.25bn USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼